Gait variability is alerted in cancer survivors with self-reported neuropathy

Katherine L. Hsieh, Linda Trinh, Jacob J Sosnoff

Research output: Contribution to journalArticle

Abstract

Background: Falls are prevalent among cancer survivors, and neuropathy, a side effect from chemotherapy treatment, is thought to contribute to falls. While falls commonly occur during walking, there is limited information about gait function in cancer survivors with neuropathy.Research Question: What is the difference between gait speed and gait variability in cancer survivors with and without self-reported neuropathy and healthy controls? Methods: Seventeen cancer survivors and 12 healthy individuals [age: 53.5 (11.8), gender: 10 females] participated in a single testing session. Cancer survivors were grouped into neuropathy [n = 9; age: 61.9 (6.1); gender: 8 females] and no neuropathy [n = 8; age: 50.75 (14.1); gender: 7 females] based on the self-reported FACT/GOG Neurotoxicity subscale questionnaire. All participants completed two walking trials at their comfortable pace across a 6 m pressure sensitive walkway. A one-way ANOVA with Tukey's post-hoc analysis and effect sizes were used to detect differences in gait speed, step length variability, and step width variability between groups. Results: Although there were no group differences in gait speed, a significant main effect was found for step length variability (p = 0.03, η2 = 0.24) between groups. Step length variability was significantly less in cancer survivors with neuropathy than healthy controls (p = 0.05, d = 1.30). There was a significant main effect for step width variability between groups (p = 0.05, η2 = 0.20). Cancer survivors with neuropathy had significantly greater step width variability than healthy controls (p = 0.04, d = 1.04). Significance: Cancer survivors with neuropathy display greater step width variability and less step length variability than healthy controls. Gait variability may be a more sensitive marker than gait speed to track mobility in cancer survivors with neuropathy symptoms. Assessing and treating gait function in cancer survivors with neuropathy symptoms may improve everyday ambulation.

Original languageEnglish (US)
Pages (from-to)206-210
Number of pages5
JournalGait and Posture
Volume72
DOIs
StatePublished - Jul 2019

Fingerprint

Gait
Neoplasms
Walking
Analysis of Variance
Pressure
Drug Therapy
Walking Speed

Keywords

  • Cancer survivors
  • Gait speed
  • Gait variability
  • Neuropathy

ASJC Scopus subject areas

  • Biophysics
  • Orthopedics and Sports Medicine
  • Rehabilitation

Cite this

Gait variability is alerted in cancer survivors with self-reported neuropathy. / Hsieh, Katherine L.; Trinh, Linda; Sosnoff, Jacob J.

In: Gait and Posture, Vol. 72, 07.2019, p. 206-210.

Research output: Contribution to journalArticle

@article{861c867fa37c4f649225fe652dd22d30,
title = "Gait variability is alerted in cancer survivors with self-reported neuropathy",
abstract = "Background: Falls are prevalent among cancer survivors, and neuropathy, a side effect from chemotherapy treatment, is thought to contribute to falls. While falls commonly occur during walking, there is limited information about gait function in cancer survivors with neuropathy.Research Question: What is the difference between gait speed and gait variability in cancer survivors with and without self-reported neuropathy and healthy controls? Methods: Seventeen cancer survivors and 12 healthy individuals [age: 53.5 (11.8), gender: 10 females] participated in a single testing session. Cancer survivors were grouped into neuropathy [n = 9; age: 61.9 (6.1); gender: 8 females] and no neuropathy [n = 8; age: 50.75 (14.1); gender: 7 females] based on the self-reported FACT/GOG Neurotoxicity subscale questionnaire. All participants completed two walking trials at their comfortable pace across a 6 m pressure sensitive walkway. A one-way ANOVA with Tukey's post-hoc analysis and effect sizes were used to detect differences in gait speed, step length variability, and step width variability between groups. Results: Although there were no group differences in gait speed, a significant main effect was found for step length variability (p = 0.03, η2 = 0.24) between groups. Step length variability was significantly less in cancer survivors with neuropathy than healthy controls (p = 0.05, d = 1.30). There was a significant main effect for step width variability between groups (p = 0.05, η2 = 0.20). Cancer survivors with neuropathy had significantly greater step width variability than healthy controls (p = 0.04, d = 1.04). Significance: Cancer survivors with neuropathy display greater step width variability and less step length variability than healthy controls. Gait variability may be a more sensitive marker than gait speed to track mobility in cancer survivors with neuropathy symptoms. Assessing and treating gait function in cancer survivors with neuropathy symptoms may improve everyday ambulation.",
keywords = "Cancer survivors, Gait speed, Gait variability, Neuropathy",
author = "Hsieh, {Katherine L.} and Linda Trinh and Sosnoff, {Jacob J}",
year = "2019",
month = "7",
doi = "10.1016/j.gaitpost.2019.06.014",
language = "English (US)",
volume = "72",
pages = "206--210",
journal = "Gait and Posture",
issn = "0966-6362",
publisher = "Elsevier",

}

TY - JOUR

T1 - Gait variability is alerted in cancer survivors with self-reported neuropathy

AU - Hsieh, Katherine L.

AU - Trinh, Linda

AU - Sosnoff, Jacob J

PY - 2019/7

Y1 - 2019/7

N2 - Background: Falls are prevalent among cancer survivors, and neuropathy, a side effect from chemotherapy treatment, is thought to contribute to falls. While falls commonly occur during walking, there is limited information about gait function in cancer survivors with neuropathy.Research Question: What is the difference between gait speed and gait variability in cancer survivors with and without self-reported neuropathy and healthy controls? Methods: Seventeen cancer survivors and 12 healthy individuals [age: 53.5 (11.8), gender: 10 females] participated in a single testing session. Cancer survivors were grouped into neuropathy [n = 9; age: 61.9 (6.1); gender: 8 females] and no neuropathy [n = 8; age: 50.75 (14.1); gender: 7 females] based on the self-reported FACT/GOG Neurotoxicity subscale questionnaire. All participants completed two walking trials at their comfortable pace across a 6 m pressure sensitive walkway. A one-way ANOVA with Tukey's post-hoc analysis and effect sizes were used to detect differences in gait speed, step length variability, and step width variability between groups. Results: Although there were no group differences in gait speed, a significant main effect was found for step length variability (p = 0.03, η2 = 0.24) between groups. Step length variability was significantly less in cancer survivors with neuropathy than healthy controls (p = 0.05, d = 1.30). There was a significant main effect for step width variability between groups (p = 0.05, η2 = 0.20). Cancer survivors with neuropathy had significantly greater step width variability than healthy controls (p = 0.04, d = 1.04). Significance: Cancer survivors with neuropathy display greater step width variability and less step length variability than healthy controls. Gait variability may be a more sensitive marker than gait speed to track mobility in cancer survivors with neuropathy symptoms. Assessing and treating gait function in cancer survivors with neuropathy symptoms may improve everyday ambulation.

AB - Background: Falls are prevalent among cancer survivors, and neuropathy, a side effect from chemotherapy treatment, is thought to contribute to falls. While falls commonly occur during walking, there is limited information about gait function in cancer survivors with neuropathy.Research Question: What is the difference between gait speed and gait variability in cancer survivors with and without self-reported neuropathy and healthy controls? Methods: Seventeen cancer survivors and 12 healthy individuals [age: 53.5 (11.8), gender: 10 females] participated in a single testing session. Cancer survivors were grouped into neuropathy [n = 9; age: 61.9 (6.1); gender: 8 females] and no neuropathy [n = 8; age: 50.75 (14.1); gender: 7 females] based on the self-reported FACT/GOG Neurotoxicity subscale questionnaire. All participants completed two walking trials at their comfortable pace across a 6 m pressure sensitive walkway. A one-way ANOVA with Tukey's post-hoc analysis and effect sizes were used to detect differences in gait speed, step length variability, and step width variability between groups. Results: Although there were no group differences in gait speed, a significant main effect was found for step length variability (p = 0.03, η2 = 0.24) between groups. Step length variability was significantly less in cancer survivors with neuropathy than healthy controls (p = 0.05, d = 1.30). There was a significant main effect for step width variability between groups (p = 0.05, η2 = 0.20). Cancer survivors with neuropathy had significantly greater step width variability than healthy controls (p = 0.04, d = 1.04). Significance: Cancer survivors with neuropathy display greater step width variability and less step length variability than healthy controls. Gait variability may be a more sensitive marker than gait speed to track mobility in cancer survivors with neuropathy symptoms. Assessing and treating gait function in cancer survivors with neuropathy symptoms may improve everyday ambulation.

KW - Cancer survivors

KW - Gait speed

KW - Gait variability

KW - Neuropathy

UR - http://www.scopus.com/inward/record.url?scp=85067874618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067874618&partnerID=8YFLogxK

U2 - 10.1016/j.gaitpost.2019.06.014

DO - 10.1016/j.gaitpost.2019.06.014

M3 - Article

C2 - 31254773

AN - SCOPUS:85067874618

VL - 72

SP - 206

EP - 210

JO - Gait and Posture

JF - Gait and Posture

SN - 0966-6362

ER -